Positive Initial Data from LOTIS-7 Trial of ZYNLONTA® in Combination with Bispecific Antibody in Patients with R/R LBCL Announced December 18, 2024
FDA granted RMAT designation to acimtamig and AlloNK (AB101) for the treatment of R/R HL December 10, 2024
FDA Clears IND Application for REC-1245, a RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma October 8, 2024
Calquence granted Priority Review in the US for patients with untreated mantle cell lymphoma October 8, 2024
Enrollment completed in Ph 2 proof of concept 065-101 study of fadraciclib in patients with advanced solid tumors and lymphoma; ongoing in T-Cell Lymphoma cohort October 2, 2024
First patient enrolled in triple combination arm of BI-1206, rituximab and Calquence® for the treatment of NHL September 18, 2024
Additional Positive Efficacy Data with BI-1808 monotherapy from Ph 2a anti-TNFR2 program Announced September 17, 2024
FDA approves BORUZU, a new presentation of bortezomib for ready-to-use subcutaneous administration or IV administration September 10, 2024
Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Ph 1b Trial in DLBCL announced September 10, 2024
NMPA approves Supplemental BLA for Carteyva® in Adult Patients with R/R Mantle Cell Lymphoma September 3, 2024
Randomized controlled trial of Nana-val in EBV-positive PTCL patients planned to begin in the second half of 2025 to support potential registration August 27, 2024
EU Approves TEPKINLY® (epcoritamab) for the Treatment of Adults with R/R Follicular Lymphoma August 27, 2024
Positive Topline Results from Tafasitamab (Monjuvi®) trial in R/R Follicular Lymphoma Announced August 22, 2024
FDA provides IND requirements for the development of ALA-101 in first-inhuman clinical trials for lymphoma and leukaemia August 13, 2024
FDA Approves LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with R/R Cutaneous T-Cell Lymphoma August 13, 2024
FDA Fast Track Designation Granted to Soquelitinib for Treatment of Patients with R/R PTCL August 6, 2024
Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma July 17, 2024
HREC Approval and CTN Clearance granted from the TGA to Commence a Ph 1 Clinical Trial for INT2104 for B Cell Malignancies July 17, 2024
Three Community Cancer Centers Activated as First Sites for the Pivotal Ph 2 ALPHA3 Trial of Cemacabtagene Ansegedleucel (cema-cel) as 1L Consolidation Treatment for Patients with LBCL July 9, 2024
NMPA accepts NDA for Tazemetostat for the Treatment of R/R Follicular Lymphoma with Priority Review Status July 9, 2024
US FDA Grants Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with R/R Follicular Lymphoma July 1, 2024
